PBS boost for melanoma patients

1 March 2020
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
All resected Stage III patients, regardless of BRAF mutation, now have subsidised access to nivolumab as adjuvant (after surgery) treatment. This is the first adjuvant immunotherapy for resected Stage III patients to be listed on the PBS, and follows clinical trials showing the therapy’s effectiveness in preventing the disease from progressing to Stage IV and spreading throughout the body.
Importantly, today’s PBS listing also includes immunotherapy as first line treatment for high risk and advanced melanoma patients who are BRAF positive. Previously, these patients were required to first undergo treatment with BRAF inhibitors and were only eligible for subsidised immunotherapy after their melanoma progressed or recurred.
Making this treatment accessible and affordable as first-line therapy for these patients will significantly increase their chances of response and long-term survival.
Today’s announcement is welcome news and a wonderful way to begin MIA's month-long awareness and fundraising campaign, Melanoma March.
‘MIA patients and their families lobbied hard for these PBS listings for many months, and this outcome is a credit to their dedication,’ said MIA Co-Medical Director Professor Richard Scolyer.
‘We thank everyone who submitted comments for consideration by the Federal Government’s PBAC, as these submissions, along with the tireless work from our team of researchers, clinicians and colleagues around the country, have now secured affordable access to these life-saving treatments for melanoma patients,’ added Co-Medical Director Professor Georgina Long.

Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.

Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.

Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

WA Melanoma Community Forum
An evening for WA melanoma patients, carers and the wider melanoma community, where speakers will provide updates on melanoma research, treatment and support.

Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.

Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.